Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM8XH3S)

Drug Name

H-1152 Drug Info

Synonyms

451462-58-1; (S)-2-METHYL-1-[(4-METHYL-5-ISOQUINOLINE)SULFONYL]-HOMOPIPERAZINE; CHEBI:88220; H-1152P; (S)-H-1152 (hydrochloride); H52; dimethyl fasudil; 4-methyl-5-{[(2S)-2-methyl-1,4-diazepan-1-yl]sulfonyl}isoquinoline; 4-methyl-5-[[(2S)-2-methyl-1,4-diazepan-1-yl]sulfonyl]isoquinoline; 2gnh; 2gnl; 1q8u; AC1L9LJA; H 1152; SCHEMBL124161; CHEMBL406821; ZINC22706; BDBM14028; BCP16935; 3714AH; AKOS027263830; DB07876; CS-1536; HY-15720; LS-193100; W-5343; 4-methyl-5-[(2S)-2-methyl-1,4-diazepane-1-sulfonyl]isoquinoline

Indication

Disease Entry	ICD 11	Status	REF
Pulmonary arterial hypertension	BB01.0	Phase 2	[1]

Cross-matching ID

PubChem CID: 448043
ChEBI ID: CHEBI:88220
CAS Number: CAS 451462-58-1
TTD Drug ID: DM8XH3S

Molecule-Related Drug Atlas

Molecule Type:

DTT

DOT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Rho-associated protein kinase 1 (ROCK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Netarsudil	DM0LPI9	Open-angle glaucoma	9C61	Approved	[4]
SAR-407899	DMF95KD	Diabetic nephropathy	GB61.Z	Phase 2	[5]
INS-117548	DMA46DO	Glaucoma/ocular hypertension	9C61	Phase 1	[6]
GSK269962A	DM5I2HL	Inflammation	1A00-CA43.1	Clinical trial	[7]
PMID28048944-Compound-19	DMPT3V9	N. A.	N. A.	Patented	[8]
PMID28048944-Compound-3	DM1BN74	N. A.	N. A.	Patented	[8]
PMID28048944-Compound-7	DMXZ368	N. A.	N. A.	Patented	[8]
PMID28048944-Compound-4	DMJAUWG	N. A.	N. A.	Patented	[8]
PMID28048944-Compound-5	DMAB987	N. A.	N. A.	Patented	[8]
PMID28048944-Compound-6	DM5RCBV	N. A.	N. A.	Patented	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Heat shock factor protein 1 (HSF1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[9]
SPI-1005	DM6XFHS	Reperfusion injury	ND56.Z	Approved	[3]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[3]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[10]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[11]
Ceftazidime	DM41GRA	Bacteremia	1A73	Approved	[3]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[12]
Chlorpheniramine	DM5URA2	Allergic rhinitis	CA08.0	Approved	[3]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[3]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Rho-associated protein kinase 1 (ROCK1)	TTZN7RP	ROCK1_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Heat shock factor protein 1 (HSF1)	OTYNJ4KP	HSF1_HUMAN	Gene/Protein Processing	[3]

------------------------------------------------------------------------------------

References

1	An emerging treatment option for glaucoma: Rho kinase inhibitors. Clin Ophthalmol. 2014; 8: 883-890.
2	Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19.
3	A Gene Expression Biomarker Predicts Heat Shock Factor 1 Activation in a Gene Expression Compendium. Chem Res Toxicol. 2021 Jul 19;34(7):1721-1737. doi: 10.1021/acs.chemrestox.0c00510. Epub 2021 Jun 25.
4	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
5	The Rho kinase inhibitor SAR407899 potently inhibits endothelin-1-induced constriction of renal resistance arteries. J Hypertens. 2012 May;30(5):980-9.
6	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
7	Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J Pharmacol Exp Ther. 2007 Jan;320(1):89-98.
8	Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515.
9	NRF2 transcriptionally activates the heat shock factor 1 promoter under oxidative stress and affects survival and migration potential of MCF7 cells. J Biol Chem. 2018 Dec 14;293(50):19303-19316. doi: 10.1074/jbc.RA118.003376. Epub 2018 Oct 11.
10	Non-steroidal anti-inflammatory drugs inhibit the expression of cytokines and induce HSP70 in human monocytes. Cytokine. 1999 May;11(5):347-58. doi: 10.1006/cyto.1998.0437.
11	Simvastatin induces heat shock factor 1 in vascular endothelial cells. Atherosclerosis. 2006 Oct;188(2):265-73. doi: 10.1016/j.atherosclerosis.2005.10.045. Epub 2005 Dec 20.
12	Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.